Mike Bassett is a journalist who writes for MedPage Today, covering a wide range of medical and healthcare topics. His articles provide in-depth analysis and reporting on issues such as drug overdoses, cancer diagnoses, clinical trials, and advancements in medical treatments. Mike's work has also appeared in Knowledia, further showcasing his expertise in the field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Mike Bassett's articles predominantly focus on healthcare and pharmaceuticals, with a particular emphasis on cancer research, medical treatments, clinical trials, and oncology. His coverage heavily relies on data citations.
When reaching out to Mike Bassett, consider providing data-driven insights or expert commentary related to the latest developments in cancer research and medical treatments. Pitches should be backed by credible data sources and provide valuable analysis or interpretation of scientific findings within these areas of interest.
Given his broad spectrum of topics covered under healthcare & pharmaceuticals, pitches must offer unique perspectives supported by reliable scientific evidence or recent breakthroughs in the field.
This information evolves through artificial intelligence and human feedback. Improve this profile .
— Increased factor VIII levels to mild or moderate range, with annualized bleeding rate of zero
By: Mike Bassett
— Benefit seen in all prespecified subgroups, including high-risk patients
— However, imlunestrant failed to improve PFS among entire trial population
By: Mike Bassett
— Lower rates of mortality and cancer recurrence with mastectomy, salpingo-oophorectomy
By: Mike Bassett
— Study results are "historic," expert says SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following
By: Mike Bassett
— Radiotherapy also resulted in fewer treatment-related adverse events
By: Mike Bassett
Study results are 'historic,'expert says SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following
By: Mike Bassett
— Study was stopped early due to enrollment issues, but lessons can still be learned
PD-L1 inhibitor indicated for metastatic or locally advanced disease
In randomized study, ensartinib doubled PFS versus first-generation ALK inhibitor
(833) 317-6278 
